Safety and Efficacy Data: The CheckMate 214 Trial
Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.
Facing Unmet Needs and Ongoing Trials in RR-DTC
Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.
Patient Scenario 2: Selecting Therapy for mHSPC
Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.
PSMA-Targeted Therapy for nmCRPC
A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.
Scott T. Tagawa, MD, Talks Current Initiatives in Prostate Cancer
Scott T. Tagawa, MD, spoke about potential approvals in the coming year for prostate cancer.
Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma
Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment
An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.
Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib
Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.
Risk Factors in the Management of Advanced Renal Cell Carcinoma
Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.
Treatment Options in RAI-refractory DTC in Second Line and Beyond
Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.
CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies
Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.
BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment
An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.
Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.
Outcomes with Daratumumab in Frontline Versus Subsequent Lines of Therapy in Transplant-Ineligible MM
A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.
Marina Frimer, MD, Talks Future Treatments in Uterine Cancer
Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.
Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens
David Aggen, MD, PhD identifies patient populations who may benefit from single-agent therapy and reviews NCCN recommendations for first-line treatment of metastatic clear cell RCC.
Evolution of Combination Therapy As The Standard of Care
Robert Alter, MD, weighs in on the evolution of combination therapy as the first-line standard of care for patients with metastatic clear cell RCC.
Sam Klempner, MD, Discusses Minimal Residual Disease in Gastrointestinal Cancers
Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.
Newer First-Line Combination Therapy Options
David Aggen, MD, PhD touches on the availability of newer first-line combination treatment options for metastatic disease.
Comparison of Older First-Line, Single-Agent Therapies
Robert Alter, MD compares older, single-agent first line therapies for patients with metastatic clear cell RCC.
